Engitix Therapeutics
PrivateLast Round
Series A
Extension
Jan 8, 2026
Total Funding Raised
$86M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Engitix Therapeutics is a biotechnology company that develops therapies for cancer and fibrosis by targeting the extracellular matrix (ECM).
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engitix Therapeutics Comparables
Compare Engitix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Apmonia Therapeutics | 76% | |
| Telescope Therapeutics | 69% | |
| Aspect Biosystems | 66% |
Engitix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 8, 2026 | ||||
| Series A | Jan 19, 2022 | ||||
| Seed | Nov 27, 2018 |
Key People
Founding team and executive leadership
Engitix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Netherton Investments | Seed, Series A, Series A Extension |
| UCL Business | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 34% MoM, reaching 4.3K.
- Jul 24, 2026
Monthly visitors increased 270% MoM, reaching 3.2K.
Recent news
Latest coverage and updates
- hiresSep 23, 2026
Engitix hired Sonia Quaratino as Executive Vice President (EVP) Chief Medical Officer on Sep 23rd '26.
- hiresSep 23, 2026
Engitix hires Sonia as EVP Chief Medical Officer.
- is_developingJul 28, 2026
Engitix is developing antibody-drug conjugates generation.
- is_developingJul 28, 2026
Engitix is planning to develop targeted therapeutics.
- is_developingJul 23, 2026
Engitix Ltd is developing differentiated therapeutic candidates.
Engitix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Engitix Therapeutics's valuation, stock price, and market status.
Is Engitix Therapeutics a public or private company?
Engitix Therapeutics is a private company.
What is the current stock price of Engitix Therapeutics?
Engitix Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Engitix Therapeutics worth (valuation)?
Valuation information for Engitix Therapeutics is not publicly available.
Can I buy Engitix Therapeutics stock?
Engitix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Engitix Therapeutics's last funding round?
Engitix Therapeutics's most recent funding round was Series A Extension on January 8, 2026.
Who are the main investors in Engitix Therapeutics?
Key investors in Engitix Therapeutics include Netherton Investments.
Will Engitix Therapeutics IPO soon?
No public IPO plans have been announced for Engitix Therapeutics.
How can I track Engitix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Engitix Therapeutics's secondary market activity and sign up for updates.